COSCIENS Biopharma Inc

COSCIENS Biopharma Inc(CSCI)の株式分析

$2.720

-0.318 (-11.69%)終値時点

Loading chart…
High
2.975
Open
2.960
VWAP
2.73
Vol
58.61K
Mkt Cap
Low
2.500
Amount
160.11K
EV/EBITDA, TTM
0.00

COSCIENS Biopharma Inc. is a Canada-based life science company. The Company is developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical and pharmaceutical markets. The Company’s patented technologies include the Pressurized Gas eXpanded (PGX) technology, which is a technology that generates high-value yields of active ingredients from natural-based resources for use in novel cosmeceutical, nutraceutical and pharmaceutical products. The Company's two products, oat beta glucan and avenanthramides, are found in household-name cosmetic and personal care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Its lead product, macimorelin (Macrilen; Ghryvelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).

バリュエーション指標

The current forward P/E ratio for COSCIENS Biopharma Inc (CSCI) is 0.16, compared to its 5-year average forward P/E of -1.33.

Forward P/E

Fair
5Y Average P/E
-1.33
Current P/E
0.16
割高
0.36
割安
-3.02

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-0.03
Current EV/EBITDA
0.00
割高
0.04
割安
-0.10

Forward P/S

Fair
5Y Average P/S
5.20
Current P/S
0.79
割高
11.36
割安
-0.96

イベントタイムライン

2025-05-26 (ET)

07:46:02

Cosciens Biopharma announces receipt of Goodwood intended director nominations

2025-04-14 (ET)

07:11:52

Cosciens Biopharma appoints Biehn as CEO

2025-03-19 (ET)

19:04:37

Cosciens Biopharma announces possible delay in filing 2024-end documents

2025-03-13 (ET)

07:58:39

Cosciens Biopharma announces initiation of Phase 2a study for avenanthramides

2024-12-23 (ET)

06:49:59

Cosciens Biopharma provides update, reiterates pipeline prioritization

ニュース

CSCI FAQ — answered by Alphio AI

COSCIENS Biopharma Inc. is a Canada-based life science company. The Company is developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical and pharmaceutical markets. The Company’s patented technologies include the Pressurized Gas eXpanded (PGX) technology, which is a technology that generates high-value yields of active ingredients from natural-based resources for use in novel cosmeceutical, nutraceutical and pharmaceutical products. The Company's two products, oat beta glucan and avenanthramides, are found in household-name cosmetic and personal care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Its lead product, macimorelin (Macrilen; Ghryvelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). It operates in the Healthcare sector.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める